AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Generex reports advance in cancer immunotherapy.
2004 MAY 5 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corp. (GNBT) announced its recent report at the American Association for Cancer Research in Orlando, Florida, on a novel approach to cancer vaccination developed by scientists and collaborators at its Antigen Express subsidiary.
About 1500 cancer clinicians and researchers from around the world attended this conference.
Dr. Eric von Hofe, vice president, technology development at Antigen Express, who presented this report, said: "This technology is revolutionary in the sense that we bioengineer cancer cells to present their antigenic epitopes directly to T helper lymphocytes. That process improves the speed and power of antigenic stimulation of the T helper cells. In turn, there is a better cytotoxic T lymphocyte and antibody response to the tumor."
The Antigen Express technology induces special receptors for endogenous tumor antigenic peptides, the Major Histocompatibility Complex (MHC) class II molecules, in the absence of the ...
- Generex Biotechnology Completes Acquisition of Antigen Express.
- Press release article from: PR Newswire August 11, 2003 700+ words
...shares in the capital of Antigen Express, Inc. in exchange for approximately...Officer and a director of Antigen Express. Dr. Gulfo is also expected...of directors of Generex. Antigen Express will operate as a wholly...
- Generex Biotechnology Announces Proposed Acquisition of Antigen Express, Inc.
- Press release article from: PR Newswire June 5, 2003 700+ words
...of the shares of privately-owned Antigen Express, Inc. in exchange for a maximum...depends on satisfaction of certain Antigen Express performance milestones over the next...Respiratory Syndrome) vaccines with Antigen Express. These vaccines combine the Company...
- Antigen Express Announces Phase I SBIR Grant for Development of MHC Class II...
- Press release article from: PR Newswire April 5, 2001 700+ words
...Mass., April 5 /PRNewswire/ -- Antigen Express, Inc. (AgExp) today announced...dendritic cell based therapeutics. Antigen Express researchers have shown that cancer...metastasizing prostate cancer cell line, Antigen Express researchers aim to first induce MHC...
- Generex Biotechnology's Subsidiary Enters into Collaboration to Develop SARS...
- Press release article from: PR Newswire February 23, 2004 700+ words
...which can be used in a DNA vaccine. Antigen Express, Generex's subsidiary, has developed...protection against SARS infections. Antigen Express' technology focuses on modulating...DNA vaccines. "The heart of the Antigen Express technology platform is controlling...
- United States Awards Patent to Antigen Express Subsidiary of Generex...
- Press release article from: PR Newswire January 27, 2005 700+ words
...that its wholly owned subsidiary, Antigen Express, has received United States Patent...the Chief Scientific Officer of Antigen Express has spent his lifetime understanding...Recently he and his colleagues at Antigen Express have discovered and patented novel...
- NIH Awards HIV Grant to Antigen Express for Novel T-Helper Cell-Expanding Virus...
- Press release article from: PR Newswire May 23, 2003 700+ words
...novel HIV DNA vaccine incorporating Antigen Express proprietary platform technology for...eradicating HIV in infected individuals. Antigen Express scientists have pioneered strategies...presented, and at higher concentrations. Antigen Express scientists and collaborators already...
- Generex Biotechnology Announces SARS Vaccine Research & Development...
- Press release article from: PR Newswire May 22, 2003 700+ words
...collaborate with privately-owned Antigen Express, which will use its proprietary Ii...enhancement of immunity in animal models. Antigen Express has shown significantly enhanced immunogenicity...peptide technologies. Recently, Antigen Express was awarded a $357,000 Phase I...
- Generex Biotechnology's Subsidiary Antigen Express Initiates Clinical Trials in...
- Press release article from: PR Newswire March 22, 2005 700+ words
...developed by its wholly owned subsidiary Antigen Express. The compound, AE37, is being tested...prevention, diagnosis, and treatment. Antigen Express entered into a Collaborative Research...work with Dr. Peoples to advance Antigen Express' HER-2/neu vaccine efforts for...
Source: HighBeam Research, Generex reports advance in cancer immunotherapy.